ABSTRACT
Objective To evaluate attitudes regarding privacy of genomic data in a sample of patients with breast cancer. Methods Female patients with breast cancer (n=100) completed a questionnaire assessing attitudes regarding concerns about privacy of genomic data. Results Most patients (83%) indicated that genomic data should be protected. However, only 13% had significant concerns regarding privacy of such data. Patients expressed more concern about insurance discrimination than employment discrimination (43% vs 28%, p<0.001). They expressed less concern about research institutions protecting the security of their molecular data than government agencies or drug companies (20% vs 38% vs 44%; p<0.001). Most did not express concern regarding the association of their genomic data with their name and personal identity (49% concerned), billing and insurance information (44% concerned), or clinical data (27% concerned). Significantly fewer patients were concerned about the association with clinical data than other data types ( p<0.001). In the absence of direct benefit, patients were more willing to consent to sharing of deidentified than identified data with researchers not involved in their care (76% vs 60%; p<0.001). Most (85%) patients were willing to consent to DNA banking. Discussion While patients are opposed to indiscriminate release of genomic data, privacy does not appear to be their primary concern. Furthermore, we did not find any specific predictors of privacy concerns. Conclusions Patients generally expressed low levels of concern regarding privacy of genomic data, and many expressed willingness to consent to sharing their genomic data with researchers.
BACKGROUND AND SIGNIFICANCE
Cancer therapy is increasingly personalized to the molecular characteristics of a particular patient and his/her tumor. 1 The National Cancer Institute (NCI) defines personalized cancer therapy as the 'application of genomic and molecular data to tailor medical care to individuals'. 2 Personalized cancer therapy has the potential to improve treatment response, reduce adverse effects, and reduce cost of care. 3 In this paper, we refer to personalized, precision and genomically informed cancer therapy interchangeably. Similarly, although the terms 'genetic' and 'genomic' have distinct scientific meanings, 3a we favored the more familiar 'genetic' in the questionnaire administered to patients and were not strict about the distinction.
Although patients and providers express an interest in genomically informed therapy, 4 concerns regarding the privacy of genomic data have been raised, particularly in the context of research. 5 6 Genomic data cannot be completely 'deidentified', 7 8 thus these data pose a serious privacy risk. As a result, the storage and sharing of genomic data in the context of research is presently a topic of much debate. 9 Data from a Gallup poll 10 showed that medical privacy is important to people in the general population, and privacy concerns related to genetic testing and hereditary cancers have been raised. 11 However, previous studies have asked general questions about medical privacy, such as 'Who do you think should be allowed to see your medical records without your permission?'. 10 Such questions are not representative of current research being considered or conducted where identified data are collected for specific, explicitly defined purposes. Furthermore, many studies have focused almost exclusively on healthy participants, who did not have an established relationship with a research organization where they were receiving care. Thus, previous studies may not have considered the specific privacy concerns of patients with cancer, for whom molecular testing and genetic research may have direct and indirect benefits.
Finally, little is known about patients' privacy concerns related to molecular testing in personalized cancer therapy, which mainly focuses on information related to somatic (as opposed to germline) mutations. 12 In contrast with germline mutations, somatic mutations are not heritable. Thus, from a privacy perspective, they may be less concerning to patients.
Understanding patients' privacy concerns regarding genomic data may help researchers and clinicians better address patient concerns, and may encourage participation in genomic studies. 13 Further, patients rather than the general public are the most relevant population. Our results may also help to align the public policy debate with the concerns of patients, rather than the general public.
OBJECTIVE
This study evaluated the attitudes of patients with breast cancer to privacy regarding molecular testing, including concerns about discrimination, data storage, association of identifying information, willingness to share the data, and consent to storage of test samples.
METHODS

Study population
This study was approved by the institutional review board at The University of Texas MD Anderson Cancer Center (MD Anderson). We recruited English-speaking female patients over 18 years of age with breast cancer who registered as new patients at MD Anderson between October 2012 and January 2013. Eligible patients had a prior diagnosis of breast cancer but had not yet received clinical care at MD Anderson; however, they may have previously been seen, or received care, for their breast cancer elsewhere. As part of routine practice, patients are offered the opportunity to provide informed consent for banking tissue during the registration process. Patients were eligible for the study regardless of whether they consented to tissue banking or not.
Study questionnaire
An 18-item questionnaire assessed attitudes regarding the association of personally identifying information with genomic data, risks of potential insurance and employment discrimination based on genomic information, and willingness to share genomic data (see the online appendix). We developed the questionnaire on the basis of a literature review regarding privacy and discrimination concerns about genomic data in cancer and other conditions. Thirteen questions addressed patients' privacy concerns, and five questions addressed patients' preferences for data sharing. Prior to administration, the questionnaire was reviewed for content validity and underwent pilot testing with patients recruited from MD Anderson's breast cancer clinic.
Sample size
This was a descriptive study. The sample size of 100 was chosen on the basis of acceptable precision of the estimates of means (for continuous variables) and proportions (for categorical variables) related to patients' attitudes. Specifically, for a continuous variable, when the sample size is 100, a two-sided 95% CI for a single mean will extend 0.196 from the observed mean, assuming that the SD is known to be 1 and the CI is based on the large-sample z statistic. For a binary variable, when the sample size is 100, a two-sided 95% CI for a single proportion using the large-sample normal approximation will extend 0.098 from the observed proportion for an expected proportion of 0.5. The precision will improve when the expected proportion is different from 0.5.
Patient recruitment and data collection
Of 308 eligible consecutive patients approached in a clinic waiting room and invited to participate in the study, 100 provided informed consent and completed the study questionnaire (33% response rate). The recruitment process is illustrated in figure 1 . Research staff were available to address any issues regarding completing the questionnaire.
After providing informed consent, patients completed a selfadministered questionnaire while waiting for their first appointment with an MD Anderson physician.
Patients who completed the questionnaire also consented to the research staff obtaining additional clinical data from their medical records. The study data were correlated with clinical variables obtained from patients' medical records.
Measures
Thirteen items that assessed attitudes to privacy of genomic data were included as part of a larger questionnaire regarding attitudes to personalized cancer therapy. Responses to these 13 items were measured on a Likert scale from 1 (strongly disagree) to 5 (strongly agree). The items were summed to create a composite privacy variable (Cronbach's α=0.92). Responses were dichotomized as 'negative', comprising 'neutral', 'disagree' and 'strongly disagree', and as 'positive', comprising 'agree' and 'strongly agree'. We assumed that the 'neutral' option could be considered as either undecided or ambiguous. Thus we assumed that 'neutral' responses did not reflect strong concerns about privacy. As a summary measure, patients were considered to be significantly concerned about privacy if the average numeric score of their responses across all 13 items was 'positive' (≥4). In addition, patients answered questions about race, education, income, marital status, status of having children, and family history of cancer. We recorded patients' age, insurance, and clinical variables such as duration of illness, cancer stage, history of cancer therapy, history of genetic testing, and consent to tissue banking from the patients' medical records.
Data analysis
Descriptive statistics (table 1), the Wald test using robust SEs in the generalized estimating equation (GEE) approach (table 2) , χ 2 tests of fixed (equal) proportions (table 3) , and χ 2 tests of independence (table 4) were used. Unanswered questions were excluded from the descriptive analysis and were eliminated test-by-test. We used the Wald tests with robust SEs in the GEE method to determine whether responses to groups of questions were the same. The question groups were: (1) discrimination by insurer versus employer; (2) security of data held by government agencies versus research institutions versus drug companies; (3) association of genetic data with name and identification details versus clinical information versus billing and insurance information (table 2); (4) preference to share deidentified versus identified data with researchers not involved in their care, in the absence of direct benefit.
A matrix of p values resulting from the χ 2 tests of independence was generated between responses and patient characteristics such as patient demographics, age at diagnosis, duration of illness, cancer stage, history of systemic therapy, history of genetic testing, and consent to tissue banking (table 4) . A significant individual association was determined if the p value was less than 0.05. However, in interpreting the significance of association across a large number of tests, we took into account the number of significant tests expected by chance. Missing values were eliminated test-by-test. All variables in table 4 were treated as nominal variables. 
RESULTS
Participants' demographic characteristics are described in table 1. Mean age was 55 years. Most patients were white (70%), well educated, and had annual incomes of US$50 000 or higher.
Most patients (83%) indicated that genomic data should be protected. However, only 13% of patients endorsed significant concern regarding genomic data privacy defined as an average score of 'positive' on the privacy-related questions. Patients did express more concern about insurance discrimination than employment discrimination (43% vs 28%, p<0.001) (table 2).
Patients expressed less concern about research institutions, such as comprehensive cancer centers, protecting the privacy of their molecular data compared with government agencies or drug companies (20% vs 37% vs 44%; p<0.001) (table 2). Few patients endorsed concerns regarding association of their genomic data with their name and identity, billing and insurance, or clinical data (49% vs 45% vs 27%; p<0.001) (table 2).
In the absence of direct benefit to themselves, most patients indicated that they were willing to consent to sharing both deidentified data (76%) and identified data (60%) with researchers not involved in their care. The difference between patients expressed willingness to share deidentified data and identified data was statistically significant ( p<0.001). Thirty-six per cent of patients indicated that they were willing to consent to sharing identified data with any researcher at their treating institution, and 14% with any cancer researcher (table 3). Most patients (85%) also indicated that they were willing to consent to the storage of their DNA and genetic test results, if their data were deidentified (table 3) .
In the tests for the association between variables, only four variables had significant p values (<0.05) (table 4). As we conducted a large number of tests, up to 5% of cases can have significant p values by chance, even in the absence of any association in the tests. So we concluded that demographic and clinical variables did not correlate with privacy concerns (table 4) , with all p values (the smallest being 0.01) being larger than 0.001 (=0.1/ 104), the significance level of each test based on a Bonferroni adjustment.
DISCUSSION
We assessed attitudes regarding privacy issues related to the use and sharing of genomic data in a sample of patients with breast cancer recruited from a comprehensive cancer center. Most patients indicated that genomic data should be protected. However, few reported significant privacy concerns related to genomic data. Most patients indicated that they would be willing to consent to sharing their genomic data with researchers who were not directly involved in their clinical care. Our findings on attitudes to the general protection of genomic data are similar to those of previous studies. 4 14 The study focused on newly registered female patients, most of whom had had breast cancer for less than a year (70%). Therefore, our results may not be generalizable to men or patients with other cancers or other diseases. Also, the study population was relatively well educated (78% with college degree or higher) compared with the US population (28% with college degree or higher 15 ), potentially limiting generalizability. However, we found no association between education level and privacy concerns. Further, we explored privacy concerns from a research perspective. The role of molecularly targeted therapies and genomic testing may be better established for breast cancer than for other diseases. Thus, patients with breast cancer may be more tolerant of privacy issues. We also do not know if patients' willingness to share would actually translate to increased research participation and consent to tissue banking. Although the questionnaire was piloted, we did not conduct formal reliability testing, which is a limitation. The questionnaire measured the degree of agreement using a Likert scale, and responses were consolidated into binary options for analysis. Previous studies have shown that consolidating a Likert scale to binary formats does not affect the results. 16 With a response rate of 33%, it is possible that nonparticipating patients are also unwilling to share their genomic data and are highly concerned about privacy. The relatively low response rate of 33% may be attributable to the fact that patients were not compensated. Patients were recruited in the clinic while waiting for their first appointments, and thus may not have wanted to participate because of concerns about the study interfering with their appointment. Some patients had very little time before their appointments. Patients may also have been anxious before their appointments, which may have decreased their interest in participating. We did not collect data on reasons for refusal, which is another limitation of this study. The lack of advertisement regarding the study and the fact that recruitment, informed consent, and completion of study questionnaires took place on the same day may also have decreased the response rate. Future research should be directed toward addressing these limitations in an attempt to generate more generalizable findings. In spite of these limitations, the results provide an insight and direction for further exploration.
In contrast with previous studies, 10 17 we enrolled patients with cancer rather than the general public. We conducted the study at a research institution that offers molecular testing and personalized cancer therapy. Patients may be likely to be offered or may seek these choices sometime during their course of treatment. Thus, a strength of our study was that we explored the privacy concerns in a sample likely to be offered molecular testing and personalized cancer therapy. Patients completed the questionnaire before their first encounter with a physician at the clinic. Thus their responses reflected opinions that were not influenced by information received from their providers at their first or future appointments. In future work, we hope to understand patients' privacy concerns as they evolve over their clinical care, which may help institutions to develop informed consent policies and patient education materials on molecular testing. Notably, participants were offered tissue banking as part of the registration process, potentially sensitizing them to data sharing and data storage issues. Therefore, patients were informed about some risks of data sharing during the informed consent process for tissue banking. However, we did not assess patients' knowledge in this area, as it was beyond the scope of our study. We did not consider privacy concerns prior to the diagnosis of cancer or any recent change in attitude; however, we included history of genetic testing, consent to tissue banking, and duration of illness in our analysis.
We found that relatively few patients endorsed significant privacy concerns, whereas a previous study found that about 90% of participants were concerned about privacy. 18 The difference may potentially be explained by the study population. Our study population comprised patients with cancer rather than persons without a specific health concern.
17 Thus, there is at least the possibility that sharing one's data could provide a direct benefit (eg, access to investigational therapies via clinical trial), an indirect benefit (eg, improved care for family members at risk of the same disease), or both. Still, our results support research showing that patients were less concerned about genetic data than social security numbers or sexually transmitted diseases. 18 These findings suggest that patients are aware of the potential harm from indiscriminate release of genomic data, but that this potential harm is not their primary concern.
Patients expressed relatively little concern regarding discrimination by employers and insurers. This contradicts prior studies that reported high concern about these types of discrimination. 17 19 One reason may be awareness of federal regulations such as the Genetic Information Nondiscrimination Act (GINA) of 2008, which protects consumers from discrimination by health insurers and employers. 20 In a related ongoing study, we are assessing whether patients are aware of federal regulations on genomic information.
Patients were least concerned about genomic data stored by research institutions, compared with government agencies, such as the Centers for Disease Control, and drug companies. Other studies have found similar results with respect to sharing data with research institutions and government agencies. 18 21 This may be because patients do not expect any benefit from institutions not involved in their clinical care and thus focus on the potential harms.
Experts have expressed concerns regarding the association of genomic data with clinical information and have suggested increased measures to protect privacy and security. 14 We found that patients were more concerned about linking identifying information and billing information to genomic data than clinical information. This may be because researchers are aware of the uniquely identifying nature of genomic data and thus focus on the risks rather than the potential benefits. For example, a recent study demonstrated the potential privacy risks from genomic data when researchers were able to reidentify anonymized genomic information using publicly available data. 22 Patients may be less aware of these advances and the risk of identification. Alternatively, they may judge the potential benefits of data sharing to outweigh the risks.
Members of the general public are willing to share genomic data if they are likely to benefit them. Specifically, they are more likely to share data that would be used for their care than for research. 21 According to the 2005 National Consumer Health Privacy Survey, only 30% of respondents were willing to share data with personnel not directly involved in their healthcare. 17 Patients in our study were also more willing to share data if these data could be used for their own clinical care. However, nearly 60% in our sample were willing to share data even in the absence of direct benefit. Cancer patients may be motivated by a hope of better future treatments resulting from research. It is also possible that patients seeking treatment at a comprehensive cancer center may be more favorably disposed to research.
Most in our study were willing to allow researchers to store deidentified genomic data and DNA samples. Previous studies have explored the acceptability of DNA banking 18 23 without a defined purpose or access rules (eg, without specifying whether the collection was for clinical care or research). In contrast with previous studies, we explored patient preferences regarding the personnel who could access banked samples and found much greater willingness to share data for research than did previous studies.
Questions 14-18 in the questionnaire were specified such that each choice was inclusive of all the previous choices. As an example, patients willing to share data with 'anyone' (choice 5) should also be willing to share data with 'any researcher' (choice 4), 'any cancer researcher' (choice 3), etc. This may have introduced an order bias if some participants selected an earlier answer, when, in fact, a later one was the most accurate. As a result, percentages choosing the options in the columns on the left of table 3 (ie, indicating less willingness to share) may have been inflated. Random permutation of these answers might have helped to reduce such potential order bias. However, since we found that most patients were willing to share data, bias related to the ordering of choices in questions 14-18 was probably not a major factor.
We found no significant correlations between privacy and demographic and clinical variables. Similar results have been obtained on patient privacy concerns about use of electronic health records. 24 However, compared with the latter study, our study is limited in power to detect significant correlations because of the small sample size (n=100).
Further studies are required to validate our questionnaires. In addition, qualitative studies are needed to understand the underlying reasons for our findings. Future work is needed to determine whether concerns change over the course of treatment.
Ideally, policies regarding the sharing of patients' genomic data should reflect their wishes and expectations. Findings from studies such as ours can help to better inform the development of such policies. As more information on potential risks from genomic data becomes available, patients' concerns may be expected to change. Thus future studies should address any changing trends and advances.
CONCLUSION
In general, patients in our study expressed low levels of concern regarding privacy of genomic data. Patients with cancer may recognize the clinical and research value of genomic testing, and a significant proportion are willing to consent to sharing of their genomic data with researchers even if they are not likely to benefit directly. Our results may inform policy regarding the collection, storage, and sharing of genomic data in a research context. Competing interests None.
